Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While Cardiff Oncology shows promise with its first-line RAS-mutated mCRC trial and a solid cash runway into Q3 2025, delays in enrollment and reliance on Pfizer Ignite pose risks. The Q&A revealed confidence in trial execution but also highlighted uncertainties, such as the delay in data readouts and lack of diversification into RAS wild-type mCRC. The financial position is stable, but the lack of new revenue streams or shareholder return plans tempers optimism. Overall, the sentiment is neutral, with potential for both positive and negative developments.
Key Financial Performance
Cash and short-term investments $67.2 million, no year-over-year change mentioned.
Cash used in operating activities $7.7 million in Q1 2024, no year-over-year change mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Onvansertib: Onvansertib is being added to the current standard of care for first line treatment of RAS mutated metastatic colorectal cancer (mCRC).
Combination Therapy: Onvansertib displayed robust anti-tumor activity as a single agent and in combination with cetuximab for RAS wild type mCRC.
Small Cell Lung Cancer: Onvansertib is planned to be combined with paclitaxel for treating extensive stage small cell lung cancer.
Ovarian Cancer: Onvansertib showed synergistic effects with carboplatin and gemcitabine in high-grade serious ovarian cancer models.
Market Expansion: Focus on first line treatment of RAS mutated mCRC, addressing a patient population of almost 50,000 new patients annually in the U.S.
Clinical Trials: Ongoing CRDF-004 trial for first line RAS mutated mCRC with plans to enroll 90 patients.
Cash Position: Cash and short-term investments totaled $67.2 million as of March 31, 2024.
Operating Cash Flow: Cash used in operating activities was $7.7 million in Q1 2024.
Clinical Development Strategy: Emphasis on adding onvansertib to standard care in first line RAS mutated mCRC.
Partnership with Pfizer Ignite: Collaboration with Pfizer for the execution of the CRDF-004 trial.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expectations.
Clinical trial risks: The timing of the initial data readout for the CRDF-004 trial has been adjusted to Q3/Q4 2024 due to slower than anticipated enrollment trends at activated clinical trial sites.
Regulatory risks: The company is subject to regulatory scrutiny and must comply with FDA regulations, which can impact the approval and market introduction of their therapies.
Financial risks: The company reported cash and short-term investments of $67.2 million, with cash used in operating activities at $7.7 million in Q1 2024, indicating a need for careful financial management to sustain operations.
Competitive pressures: The company faces competition in the oncology market, particularly in the treatment of RAS mutated mCRC, where there have been no new therapies approved in 20 years.
Supply chain challenges: The company relies on partnerships, such as with Pfizer Ignite, for clinical trial execution, which introduces risks related to operational execution and resource availability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Clinical Development Focus: Cardiff Oncology's clinical development plan for onvansertib is focused on first line treatment of RAS mutated metastatic colorectal cancer (mCRC), addressing a significant patient population with no new therapies approved in 20 years.
CRDF-004 Trial: The ongoing Phase 2 trial (CRDF-004) is evaluating first line patients with RAS mutated mCRC, with plans to enroll 90 patients randomized to receive different dosages of onvansertib plus standard care.
Data Presentation at AACR: Five posters were presented at the AACR annual meeting, supporting the first-line strategy in mCRC and demonstrating onvansertib's efficacy in various cancer types.
Combination Therapy Strategy: The company is exploring combination therapies of onvansertib with standard treatments in multiple cancer types, including small cell lung cancer and ovarian cancer.
Initial Data Readout Timing: The initial data readout from the CRDF-004 trial is now expected in the second half of 2024 (Q3/Q4), based on enrollment trends.
Financial Position: As of March 31, 2024, cash and short-term investments totaled $67.2 million, providing a cash runway into the third quarter of 2025.
Operating Cash Usage: Cash used in operating activities was $7.7 million in Q1 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash and short-term investments: $67.2 million as of March 31, 2024.
Cash used in operating activities: $7.7 million in Q1 2024.
Cash runway: Current resources provide cash runway into the third quarter of 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you clarify how much of the small push out was really the enrollment pace once sites are open versus maybe just some delays getting the sites up and running as quickly as you'd hoped?
A:There is a high amount of enthusiasm from principal investigators due to the novel option onvansertib provides in the first line setting. The push out in data sharing is due to the pace of enrollment and the need for a more accurate projection, now expected in Q3/Q4 2024.
Q:Can you review some of the scenario planning regarding the data? Is there a scenario where it could get shut down from a futility perspective or accelerate plans for CRDF-005?
A:We will be looking to share initial data in Q3/Q4 with approximately half the patients having at least one post-baseline scan. The CRDF-004 is a dose confirmation trial, and faster FDA engagement is beneficial.
Q:Is there a possibility of seeing another cut of the ONSEMBLE cohort before the CRDF-004 data?
A:We do not have plans for continued follow-up of the ONSEMBLE data after the robust data set announced on February 29.
Q:Can you elaborate on the potential to explore RAS wild type CRC in a future pivotal front line trial?
A:We are evaluating trial design for RAS wild type but have not made any moves yet. Our focus remains on CRDF-004.
Q:Is your end goal to have 30 total clinical sites by the end of enrollment completion?
A:Our goal is to activate 35 sites, and the process is dynamic; sites may be replaced if not performing.
Q:Is it conceivable to bring two doses into the pivotal study? What else is the FDA looking for before giving the okay to start a pivotal study?
A:We do not expect to go into the registration trial with two doses; we plan for a single dose. The FDA looks for differences in efficacy and safety between doses.
Q:Can you provide a big picture view of potential data readouts in the first three quarters of 2025?
A:We are not prepared to set dates on ongoing investigator-initiated trials but are focused on the CRDF-004 trial.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the potential data readouts in the first three quarters of 2025, stating they are not prepared to set dates on ongoing trials.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AACR RAS
AACR evidence
American Association
Cancer Research
FDA
ONSEMBLE
PDX model
Phase trial
RAS mCRC
RAS mutation
RAS type
bev
cell lung
cetuximab
combination onvansertib
confirmation
course
dos
focus
lung cancer
mCRC patient
moment
monotherapy
naïve patient
onvansertib care
onvansertib paclitaxel
pace
patient RAS
point
poster
rationale
scenario
summary
thing
timing readout
trial onvansertib
type mCRC
CRDF Transcript
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Unknown2-27
The earnings call presents a balanced picture. Financially, the company shows a solid cash position and runway, but faces risks from regulatory changes and market competition. The Q&A reveals positive clinical progress but lacks clarity on timelines, which could concern investors. The $40 million capital raise is a positive, but the absence of specific guidance and potential delays in trials offset this. Overall, the sentiment is neutral as positives are balanced by uncertainties and risks.
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
Unknown8-10
The earnings call summary presents a mixed outlook. Financials show a stable cash position with a runway until Q3 2025, but high cash usage raises financial sustainability concerns. Clinical developments are promising, particularly in mCRC and ovarian cancer, yet regulatory and competitive risks loom large. The Q&A session reveals steady trial enrollment and strategic partnerships, but lacks clarity on scientific validation. Overall, the balance of positive clinical updates and financial/market risks suggests a neutral stock price movement in the near term.
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
Unknown5-3
The earnings call presents a mixed outlook. While Cardiff Oncology shows promise with its first-line RAS-mutated mCRC trial and a solid cash runway into Q3 2025, delays in enrollment and reliance on Pfizer Ignite pose risks. The Q&A revealed confidence in trial execution but also highlighted uncertainties, such as the delay in data readouts and lack of diversification into RAS wild-type mCRC. The financial position is stable, but the lack of new revenue streams or shareholder return plans tempers optimism. Overall, the sentiment is neutral, with potential for both positive and negative developments.
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
Unknown3-1
The earnings call indicates a neutral sentiment. While the company has a solid cash runway and a promising partnership with Pfizer Ignite, there are significant risks, including clinical and regulatory challenges, high cash burn, and safety concerns. The Q&A revealed some hesitancy from management to provide detailed responses, which may raise investor concerns. Although there is potential for positive developments, the lack of immediate catalysts and the uncertainties surrounding trial outcomes and market differentiation suggest a neutral stock price movement in the near term.
CRDF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
